Welcome to our dedicated page for IDEAYA Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on IDEAYA Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to five newly hired employees on April 30, 2026 under its 2023 Inducement Plan. An aggregate of 237,800 options were granted at an exercise price of $29.10 per share, equal to the April 30 closing price.
The options have a 10-year term and vest over four years (25% after one year, then monthly over three years), subject to continued service.
IDEAYA (NASDAQ: IDYA) will initiate an FDA RTOR submission for darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma following positive Phase 2/3 OptimUM-02 topline results. The trial met its primary endpoint: PFS 6.9 vs 3.1 months (HR 0.42; 95% CI 0.30-0.59; p<0.0001).
IDEAYA plans the first RTOR pre-submission in May and expects NDA completion in H2 2026; full results to be presented at ASCO 2026.
IDEAYA Biosciences (Nasdaq: IDYA) will present complete Phase 2/3 registrational data from the OptimUM-02 trial of darovasertib plus crizotinib in 1L HLA*A2-negative metastatic uveal melanoma at ASCO 2026.
The late-breaking oral presentation (LBA9503) is scheduled for June 1, 2026, 8-11AM CDT in the Melanoma/Skin Cancers session; Dr. Marlana Orloff will present additional data not included in prior topline disclosure.
IDEAYA (NASDAQ: IDYA) and Servier reported positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma. The combination improved median PFS to 6.9 months vs 3.1 months (HR 0.42; 95% CI 0.30-0.59; p<0.0001) and ORR to 37.1% vs 5.8% (p<0.0001), including five complete responses. Median DOR was 6.8 months. Safety was manageable with known adverse events; serious treatment-related events were single-digit percent. An NDA submission is planned for H2 2026 and full data will be presented at a major 2026 medical conference.
IDEAYA (NASDAQ: IDYA) will release topline results from the Phase 2/3 OptimUM-02 trial on Monday, April 13, 2026 at 8:00 a.m. ET. The trial evaluates darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma.
A joint IDEAYA and Servier pre-market release will be followed by a conference call and webcast; a replay will be available on IDEAYA's website for 30 days.
IDEAYA (NASDAQ: IDYA) announced first‑patient‑in for a Phase 1 dose‑escalation trial of IDE574, a potential first‑in‑class oral dual inhibitor of KAT6 and KAT7, on April 6, 2026. The trial will evaluate safety, pharmacokinetics, and monotherapy efficacy in solid tumors including breast, prostate, colorectal, and lung cancer.
IDE574 shows single‑digit to low‑teen nanomolar cellular potency, ~350‑to‑2,000x selectivity versus KAT5/KAT8, and superior preclinical monotherapy durability versus KAT6 selective inhibitors; a preclinical profile will be presented at AACR 2026.
IDEAYA (NASDAQ: IDYA) announced first-patient-in (FPI) for a Phase 1 combination study of IDE849 (DLL3-targeting TOP1 ADC) plus IDE161 (PARG inhibitor) in DLL3-upregulated solid tumors, including SCLC, NETs, NECs, and melanoma.
The ongoing global IDE849 Phase 1 program is evaluating 3.5 mg/kg IV Q3W in dose escalation and a 2.4 mg/kg IV Q3W expansion cohort where multiple RECIST v1.1 partial responses were observed; a clinical data update is planned for H2 2026.
IDEAYA Biosciences (NASDAQ: IDYA) announced inducement grants on March 26, 2026 of non-qualified stock options totaling 49,000 shares to two newly hired employees under the 2023 Inducement Plan.
The options carry an exercise price of $32.09 (closing price on grant date), a 10-year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced investor events and updated timing guidance for topline results from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma. The company projects a database lock in the first half of April, followed by topline data analysis and a live investor webcast.
Management will host live webcasts and fireside chats at Bank of America Merrill Lynch (May 12, 2026) and Stifel Targeted Oncology Virtual Forum (May 19, 2026); replays will be available for 30 days and preregistration will be provided on IDEAYA's investor events page.
IDEAYA Biosciences (NASDAQ: IDYA) announced abstracts for three poster presentations at AACR Annual Meeting, April 17-22, 2026 in San Diego. Presentations cover preclinical data for IDE034 (PTK7/B7-H3 TOP1 bispecific ADC), IDE574 (KAT6/7 inhibitor) and IDE892 (PRMT5 inhibitor).
Each program is in Phase 1 clinical study evaluating safety, tolerability, PK and efficacy across large solid tumors. Poster details include dates, session titles, poster numbers and availability on the company website after the meeting.